Japan Tissue Engineering Co (TSE:7774) Notes Receivable: 円0 Mil (As of Mar. 2026)


TSE:7774 Japan Tissue Engineering Co Ltd TSE:7774
60 GF Score
Price 円630.00
GF Value 円517.18
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Japan Tissue Engineering Co Notes Receivable?

Japan Tissue Engineering Co TSE:7774 -0.32% 60 Notes Receivable is 円0 Mil as of Mar. 2026. GuruFocus rates TSE:7774 with a GF Score™ of 60/100 and a GF Value™ of 円517.18 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Japan Tissue Engineering Co's Notes Receivable for the quarter that ended in Mar. 2026 was 円0 Mil.

Japan Tissue Engineering Co Notes Receivable Related Terms

Japan Tissue Engineering Co Notes Receivable Historical Data

* Premium members only.

The historical data trend for Japan Tissue Engineering Co's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Japan Tissue Engineering Co Notes Receivable Chart

Japan Tissue Engineering Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Japan Tissue Engineering Co Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:7774
60GF Score
Japan Tissue Engineering Co Ltd TSE:7774
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Japan Tissue Engineering Co Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of 円0 Mil mean?
Japan Tissue Engineering Co (TSE:7774) has a Notes Receivable of 円0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Japan Tissue Engineering Co and its competitors.
Is Japan Tissue Engineering Co's Notes Receivable too high?
Japan Tissue Engineering Co's current Notes Receivable is 円0 Mil. Overall, Japan Tissue Engineering Co has a GF Score™ of 60/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Japan Tissue Engineering Co's Notes Receivable compare to VRTX and REGN?
Japan Tissue Engineering Co's Notes Receivable of 円0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Japan Tissue Engineering Co and its competitors. Japan Tissue Engineering Co's current Notes Receivable is 円0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Japan Tissue Engineering Co stock overvalued right now?
Based on GuruFocus' analysis, Japan Tissue Engineering Co (TSE:7774) is currently considered Modestly Overvalued. The stock's GF Value™ is 円517.18, compared to a current price of 円630.00 — trading 21.8% above its estimated fair value. The current Notes Receivable is 円0 Mil. Japan Tissue Engineering Co's overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Japan Tissue Engineering Co (TSE:7774), the current Notes Receivable is 円0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Japan Tissue Engineering Co (TSE:7774) Overvalued in 2026?

Based on GuruFocus' analysis, Japan Tissue Engineering Co stock appears to be overvalued. The current stock price of 円630.00 is trading 21.8% above its estimated GF Value™ of 円517.18. GuruFocus considers Japan Tissue Engineering Co to be Modestly Overvalued.

Key valuation signals for TSE:7774:

  • Notes Receivable: 円0 Mil
  • GF Value™: 円517.18 vs. price of 円630.00 (21.8% above fair value)
  • GF Score™: 60/100 with 2 warning signs

No single metric tells the full story. See the TSE:7774 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Japan Tissue Engineering Co Business Description

Address 6-209-1 Miyakitadori, Gamagori, Aichi, JPN, 443-0022
Japan Tissue Engineering Co Ltd is a bio-venture enterprise. It is engaged in the development, manufacture, and sale of tissue-engineered medical products and related products. It operates through the Regenerative Medicine, and Research and Development support business segments. The main business goal is to use autologous culturing techniques to develop tissue-engineered medical products and then to manufacture and sell these same tissue-engineered products to medical institutions for medical treatment. The company's tissue-engineered medical products are used in autologous transplant cases, where living cells are taken from the actual patient himself, cultured and then transplanted back to that same patient.
60GF Score

Get the complete analysis for TSE:7774

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円630.00
Price
円517.18
GF Value